- Home
- DSP vs TIL Comparison
DSP vs TIL Comparison
Compare DSP & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- TIL
- Stock Information
- Founded
- DSP 1999
- TIL 2018
- Country
- DSP United States
- TIL United States
- Employees
- DSP N/A
- TIL N/A
- Industry
- DSP EDP Services
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- DSP Technology
- TIL Health Care
- Exchange
- DSP Nasdaq
- TIL Nasdaq
- Market Cap
- DSP 220.3M
- TIL 230.1M
- IPO Year
- DSP 2021
- TIL 2021
- Fundamental
- Price
- DSP $12.70
- TIL $27.56
- Analyst Decision
- DSP Strong Buy
- TIL Buy
- Analyst Count
- DSP 8
- TIL 5
- Target Price
- DSP $21.75
- TIL $119.00
- AVG Volume (30 Days)
- DSP 231.1K
- TIL 510.3K
- Earning Date
- DSP 08-11-2025
- TIL 08-12-2025
- Dividend Yield
- DSP N/A
- TIL N/A
- EPS Growth
- DSP N/A
- TIL N/A
- EPS
- DSP 0.13
- TIL N/A
- Revenue
- DSP $306,484,000.00
- TIL N/A
- Revenue This Year
- DSP $18.36
- TIL N/A
- Revenue Next Year
- DSP $15.95
- TIL N/A
- P/E Ratio
- DSP $97.95
- TIL N/A
- Revenue Growth
- DSP 30.64
- TIL N/A
- 52 Week Low
- DSP $8.70
- TIL $9.62
- 52 Week High
- DSP $26.33
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- DSP 40.59
- TIL 51.84
- Support Level
- DSP $12.32
- TIL $27.01
- Resistance Level
- DSP $13.26
- TIL $42.79
- Average True Range (ATR)
- DSP 0.63
- TIL 5.01
- MACD
- DSP -0.11
- TIL -1.00
- Stochastic Oscillator
- DSP 16.14
- TIL 9.82
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.